| Schedule of Intangible Assets |
Intangible assets were as follows as of November 30, 2022 and 2021:
|
|
|
|
|
|
|
|
|
|
|
|
|
Useful lives |
|
November 30, 2022 |
|
|
November 30, 2021 |
|
Patents |
|
10-20 years |
|
$ |
697,744 |
|
|
$ |
697,744 |
|
Less: Accumulated amortization |
|
|
|
|
(120,297 |
) |
|
|
(80,159 |
) |
License agreement |
|
10 years |
|
|
474,000 |
|
|
|
474,000 |
|
Less: Intangible asset impairment |
|
|
|
|
(185,000 |
) |
|
|
(185,000 |
) |
Less: Accumulated amortization |
|
|
|
|
(225,157 |
) |
|
|
(201,709 |
) |
Customer relationships – PrepaCyte®CB |
|
15 years |
|
|
41,000 |
|
|
|
41,000 |
|
Less: Intangible asset impairment |
|
|
|
|
(26,267 |
) |
|
|
(26,267 |
) |
Less: Accumulated amortization |
|
|
|
|
(8,711 |
) |
|
|
(7,916 |
) |
Brand |
|
1 year |
|
|
31,000 |
|
|
|
31,000 |
|
Less: Accumulated amortization |
|
|
|
|
(31,000 |
) |
|
|
(31,000 |
) |
Customer relationships – Cord:Use |
|
30 years |
|
|
960,000 |
|
|
|
960,000 |
|
Less: Accumulated amortization |
|
|
|
|
(144,000 |
) |
|
|
(112,000 |
) |
Net Intangible Assets |
|
|
|
$ |
1,463,312 |
|
|
$ |
1,559,693 |
|
|
| Schedule of Expected Amortization Expenses |
Expected amortization related to these intangible assets for each of the next five fiscal years and for periods thereafter is as follows:
|
|
|
|
|
Fiscal years ending November 30: |
|
|
|
2023 |
|
$ |
96,381 |
|
2024 |
|
$ |
96,381 |
|
2025 |
|
$ |
86,694 |
|
2026 |
|
$ |
73,132 |
|
2027 |
|
$ |
73,132 |
|
Thereafter |
|
$ |
1,037,592 |
|
Total |
|
$ |
1,463,312 |
|
|